Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975336 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of M2951 in SLE
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT02975336 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 469 participants.
The verdict
NCT02975336, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG M2951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2017-01-04 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02975336
The ClinicalTrials.gov registry entry for NCT02975336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02975336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02975336 about?
NCT02975336 is a clinical study titled "A Phase II Study of M2951 in SLE". M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT02975336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2017-01-04. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02975336?
The interventions under investigation include: Placebo (DRUG), M2951 (DRUG).
Who is sponsoring clinical trial NCT02975336?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.